Procter & Gamble Hygiene and Health Care Limited (PGHH)

Fast Moving Consumer Goods · Personal Products · NSE · Updated 5 July 2026
₹8,902 ↓ 33.32% (1Y)

🎯 Key Takeaways

  • Procter & Gamble Hygiene and Health Care Limited is navigating a transitional phase marked by declining market performance and strategic financial management, with no active growth initiatives highlighted in recent disclosures. The company remains in a mature, cash-generating phase but faces headwinds reflected in its negative one-year return and elevated valuation multiples.
  • ⚠️ Sustained underperformance in share price (-33% over 12 months) without a disclosed turnaround strategy.
Market Cap
₹31,506
P/E Ratio
36.7
Div Yield
0.00%
Promoter
0.0%

📖 The Story

Procter & Gamble Hygiene and Health Care Limited is navigating a transitional phase marked by declining market performance and strategic financial management, with no active growth initiatives highlighted in recent disclosures. The company remains in a mature, cash-generating phase but faces headwinds reflected in its negative one-year return and elevated valuation multiples.

📰 What's Happening

Recent board activity has focused on capital return and compliance rather than operational expansion. On June 22, 2026, the company proposed a final dividend of ₹60 per share for FY 2025-26, pending shareholder approval at the upcoming AGM. This follows a pattern of consistent dividend policy, though payout levels must be weighed against earnings sustainability. Additionally, on June 19, 2026, a promoter group entity transferred 1.91% of equity through an on-market sale, though management confirmed no change in overall promoter control or governance structure.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has not provided forward-looking operational guidance in the latest filings, focusing instead on procedural updates such as dividend approval timelines and TDS compliance for shareholders. The only forward-looking element is the upcoming AGM, where the ₹60 per share dividend will be voted on. No commentary on demand trends, product innovation, or market expansion was included in the recent disclosures.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Personal Products

Company MCap (₹ Cr) P/E ROCE ROE D/E
Godrej Consumer Products Limited 1.06 L Cr -234.6
Dabur India Limited 82,955 46.1
Colgate Palmolive (India) Limited 58,749 44.3
Procter & Gamble Hygiene and Health Care Limited 31,506 36.7
Gillette India Limited 25,438 41.0
Emami Limited 18,684 23.6
Cupid Limited 16,184 668.7
Honasa Consumer Limited 11,518 145.1
Bajaj Consumer Care Limited 7,020 58.5
JHS Svendgaard Laboratories Limited 80 -5.8

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Sustained underperformance in share price (-33% over 12 months) without a disclosed turnaround strategy. 2. High P/E multiple (36.7) relative to negative price momentum, suggesting valuation may not reflect earnings quality. 3. Absence of growth drivers in management commentary raises concerns about long-term earnings visibility. 4. Dividend sustainability depends on uninterrupted cash flows, which are vulnerable if underlying demand weakens further.

📋 Recent Filings

🧠 Analyst's Read

The company is currently in a defensive, income-focused phase with limited catalysts on the horizon. Investors should monitor upcoming AGM outcomes for dividend approval and any emerging commentary on demand trends or strategic initiatives. Until operational improvements or clearer growth signals emerge, the stock remains exposed to both earnings volatility and valuation compression.

Based on filing content and financial data. Not a recommendation.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-05.

📡 Get AI alerts when PGHH files new disclosures

Track PGHH filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track PGHH — Free

Free account · No credit card · 2 AI queries/day